FDA Panel: Cardiac Surgery Adhesion Barrier Use Should Be Limited To Kids
This article was originally published in The Gray Sheet
Executive Summary
SyntheMed's Repel-CV cardiac surgery adhesion barrier should be approved only for pediatric patients since pivotal trial data on newborns cannot be extrapolated to the adult population, FDA's Circulatory System Devices advisory panel recommended Sept. 19